{
  "id": 1525265,
  "title": "Jefferies cuts EyePoint stock price target to $8 on trial miss",
  "url": "https://urgent.news/2026/08/17/jefferies-cuts-eyepoint-stock-price-target-to-8-on-trial-miss",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-17T17:18:49.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/jefferies-cuts-eyepoint-stock-price-target-to-8-on-trial-miss-93CH-4863763"
  },
  "original_language": "en",
  "account": "Jefferies has reduced its price target on EyePoint Inc.'s stock to $8.00 from its previous $30.00, maintaining a Buy rating for the company. The decision comes after mixed results from EyePoint's LUGANO trial for wet age-related macular degeneration. The stock's current price is $4.66 with a market capitalization of $403 million. InvestingPro analysis suggests the stock is undervalued at a Fair Value of $12.75. Ten analysts have lowered their earnings expectations following the trial results. The primary endpoint of BCVA non-inferiority was not met due to nine patients in the DURAVYU arm experiencing vision loss from non-wAMD causes, including geographic atrophy, glaucoma, and retinal detachment. The remaining trials showed promise, with injection burden reduction and 54% of patients supplement-free at week 56. No major safety concerns were reported. EyePoint's DURAVYU treatment failed to meet its primary endpoint in the trial, but an ad hoc analysis showed non-inferiority when excluding the affected patients. Other analysts, such as Stifel and Mizuho, maintain positive ratings on the stock.",
  "summary": null,
  "key_points": [
    "Jefferies lowers EyePoint stock target to $8 from $30",
    "LUGANO trial missed primary endpoint on vision loss",
    "Stock currently at $4.66 with $403 million market cap"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}